The BHBIA Insight Exchange (formerly the Winter Seminar) is our refreshed end-of-year gathering for healthcare business insights professionals. The 2025 edition asks a critical question — how do global shifts translate into local impact for UK pharma and insights?

From Washington to Westminster, political disruption is reshaping the industry. US health policy reforms are rippling through global and European markets, raising urgent questions here in the UK. AstraZeneca leaders from both sides of the Atlantic will share their perspectives, before leading UK industry voices debate the pressures closer to home, including loss of exclusivity, restricted access, budget constraints and the threat of regionalisation. The spotlight then turns to you in an interactive session with senior UK pharmaceutical insights leaders, exploring what these shifts mean for the future of your roles, skills and partnerships.

Why attend?

The 2025 Insight Exchange offers healthcare business insights professionals a rare chance to hear directly from leaders at the edge of policy and decision-making, gain foresight into how disruption could reshape the UK market, and explore what this means for your role. You’ll leave with fresh perspectives, practical insights to apply in your work, and stronger connections with colleagues across pharma and agencies.

• Hear how US and global policy shifts could ripple into the UK market
• Gain insight into the strategic outlook for UK pharma amid rapid change
• Take part in live debate with senior pharma and agency leaders
• Connect with colleagues during the event and afterwards over networking drinks

Next Generation Complimentary Pass

For every two tickets purchased, you will receive a third ticket free of charge for a Rising Star (someone with fewer than five years’ industry experience) or a colleague who ideally hasn’t attended in the past two years. If no Rising Star is available, the pass may be used by another colleague.

Speaker Details

Dan Wygal, VP US Corporate & Government Affairs, AstraZeneca, and former General Manager, AstraZeneca Ireland

Dan leads the US Corporate & Government Affairs team and is responsible for communications, government affairs, policy and patient advocacy across AstraZeneca’s BioPharmaceutical Business Unit and Oncology Business Unit. He serves as a member of the US Leadership Team.

Before assuming his current role in 2023, he was Country President of AstraZeneca Ireland since 2021. Dan joined AstraZeneca in 2004 and has held various leadership roles, including Executive Director, Value Strategy within the US Market Access Team, where he oversaw the development and delivery of innovative value strategies, gross-to-net contract, and channel strategies for US Oncology and BioPharmaceutical Business Units. Additionally, he held roles within Market Access, Marketing, and Sales Leadership at AstraZeneca, MedImmune, and GSK.

Rick Suarez, Country President Spain and former EVP US. Market Access, AstraZeneca

Rick R. Suárez is the President of AstraZeneca Spain and Site Leader of the AstraZeneca Global Hub in Barcelona. Since joining the company in 2020, he has led a period of remarkable transformation, driving substantial sales growth and expanding the workforce from 800 to over 2,000 employees. Under his leadership, Spain has become one of AstraZeneca’s top three global leaders in clinical trials, particularly in Oncology, while the company’s corporate reputation in Spain has surged from 10th to 3rd in MRS rankings, a testament to his vision and commitment to innovation. 

Suárez’s leadership has been crucial in driving growth across multiple therapeutic areas, including Cardiovascular, Renal and Metabolism (CVRM), Respiratory, Immunology, Vaccines, and Immunotherapies. His focus on fostering public-private collaboration, enhancing market access, and aligning government relations with AstraZeneca’s broader goals has been instrumental in expanding patient access to life-changing medicines, including the Oncology portfolio. These efforts have not only advanced AstraZeneca’s market position but also resulted in strong, sustainable sales growth across the company. 

In addition to his business leadership, Suárez is a passionate advocate for talent development, diversity, and inclusion. He serves as President of the AstraZeneca Foundation in Spain, an organization dedicated to supporting young scientific talent and leads Fundamentales, an association focused on mental health in the workplace. A proud member of the LGBTI+ community, Suárez actively works to promote well-being and inclusivity across industries. 

With over 25 years of experience at AstraZeneca, Suárez has held senior roles in sales, marketing, medical affairs, market access, and government relations. Prior to his role in Spain, he served as Senior Vice President of Market Access in the U.S., where he led initiatives to improve patient access to therapies and support healthcare system sustainability.  

Pam Ganju, VP Oncology Alliance Management, EMEA & Specialist Care Business Unit Director UK & Eire, Eisai Europe Limited

Pam Ganju is a VP in Eisai’s EMEA headquarters in the U.K and is the commercial lead for their Oncology and Neurology portfolio in the UK and Ireland. She also manages the Oncology alliance for the EMEA region. In her UK role, Pam represents Eisai on the ABPI Small Companies Committee (SCC). Over the last 17 years at Eisai, Pam has held multiple roles including the Global lead for Halaven (eribulin) a novel chemotherapy agent indicated for metastastic breast cancer that has been launched world-wide. Before Eisai, Pam worked in Novartis, and Bristol Myer-Squibb, in roles spanning several aspects of drug development. Pam received her doctorate from Imperial College, University of London (UK) in Molecular Biochemistry. Her postdoctoral fellowship studies were conducted in developmental biology at the Ludwig Institute for Cancer Research (UK) and in chronic pain at the Novartis Institute for Medical Sciences.

Mark Pritchard, Partner, Healthcare Advisory, Ipsos

Mark has led our healthcare Advisory business for the last 3 years and is a commercial leader and business strategist, with a passion for healthcare transformation, technology, and market development. He has over 18 years of experience across the Healthcare industry, including Johnson and Johnson, with roles including Sales, Marketing and Commercial leadership, Consulting, Advisory, Transformation and Strategic capabilities. Mark has a broad experience working with clients across the Healthcare market, including pharma, medical devices and consumer health, spanning several specialties and therapy areas, bringing together a broad experience of working across the public healthcare sector in both primary, secondary and specialist care. His work has supported sales & marketing, large scale organisational change, service and strategy redesign, including the development and delivery of opportunity assessment, value stream and pathway mapping, go-to-market strategy, knowledge curation, launch excellence, technology landscaping, and patient and user-centric design initiatives including needs and value-based assessment and demand spaces integrating insights into actionable strategy. 

Adesola Fadiora, Innovation & AI Lead, Gilead Sciences

Adesola is Innovation & AI Lead at Gilead Sciences, where she harnesses the power of generative AI to transform customer engagement. She focuses on developing customer-centric analytics strategies that enhance decision-making, improve operational efficiency, and drive better patient outcomes. Adesola has held leadership roles across local, regional, and global markets, leading digital innovation and championing the adoption of advanced business intelligence tools. Alongside her role at Gilead, Adesola serves on the BHBIA Board of Directors, where she contributes to shaping the future of healthcare insights by fostering data literacy, embedding ethical practice, and advancing omnichannel engagement to help organisations achieve sustainable growth and deliver meaningful impact.

Kruti Popat, Commercial Excellence Director, Boehringer Ingelheim

Kruti leads a Customer Experience function at Boehringer Ingelheim and is passionate about unlocking the power of data driven decision making across the life sciences ecosystem. She brings 25 years of experience from pharma (Takeda), biotech (Galapagos Biotech) and data/strategic consultancy (IMS/IQVIA).

Watch the highlights from the Winter Seminar 2024, kindly produced by Verpora.

About the Insight Exchange

Insight Exchange is the BHBIA’s refreshed format for our traditional Winter Seminar. Keeping the spirit of our annual end-of-year gathering, it provides a collaborative space for pharma and agency colleagues to explore the issues shaping business insights today. The new format places an emphasis on live debate, practical perspectives, and peer-to-peer connection.

Delegate Fees

This event is open only to BHBIA full members.

£350 + VAT (early bird before 24th October 2025)

£390 + VAT (standard after 24th October 2025)

Cancellation Policies: for Early Bird bookings the full fee is payable with no refunds given, however a substitute delegate can be accepted. Our standard cancellation policy does not apply. For Standard bookings the standard cancellation policy applies, as stated on booking form.

Next Generation Complimentary Pass

In line with our ambition to engage a diverse community of healthcare business insights professionals in the BHBIA’s flagship events, we are delighted to introduce the Next Generation Pass.

• For every two tickets purchased, the BHBIA will provide a third identical ticket free of charge.
• Complimentary tickets should first be offered to a Rising Star (someone with fewer than five years’ industry experience).
• If no Rising Star is available, the pass may be used by another colleague.

Online Bookings - Click on the register for the event button below. Please note this is a members only event so you must be logged in as a member or to be added to your company's BHBIA existing membership register here to book online

VAT will be added when you click Register for Event

Online delegate bookings close on the 19th November 2025. The delegate list will be circulated on email prior to the event.

Venue accessibility - At Thistle Marble Arch Hotel, full disabled access is available to the event rooms and public facilities. Please click here for further information or contact admin@bhbia.org.uk.